Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging119
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions99
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?99
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study80
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer68
Best of 2022 in prostate cancer and prostatic diseases67
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis55
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro53
Sexual outcomes in men who have sex with men who underwent radical prostatectomy51
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis51
Concerns regarding prostate cancer screening guidelines in minority populations44
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States44
New BPH therapy classification: what really FITs?44
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?41
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction40
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes38
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)37
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer36
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations36
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study36
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study34
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer34
Missing the full picture: Pathology, anatomy, and operator effects in HoLEP comparisons34
Feasibility and safety study of the Flostentâ„¢ system (RAPID-I)34
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure33
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer33
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms33
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database33
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer32
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study32
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts31
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions31
0.42978096008301